Clinical Trial Update: Dapagliflozin Post Marketing Surveillance in HF and CKD

View source ↗

Summary

A post-marketing surveillance study of dapagliflozin in patients with heart failure and chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure, Chronic Kidney Disease | Status: COMPLETED